Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Recruiting · NCT05668962 · Registry updated 2024-12-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid gland carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Recruiting | Phase 2 | 2024-12-12 | NCT05668962 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Massachusetts General Hospital | 758 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| Massachusetts General Hospital | Boston | United States | 39 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| MedStar Washington Hospital Center | Washington D.C. | United States | 207 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| University of Michigan | Ann Arbor | United States | 538 |